+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 2Years +
All Genders
ID06991361

Phase I Study of Ex Vivo-Expanded Regulatory T Cells with Low-Dose Interleukin-2 to Treat Steroid-Resistant Chronic Graft-versus-Host Disease

Led by Sarah Nikiforow, MD · Updated on 2026-11-04

21

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

This research investigates the use of Ex Vivo-Expanded Regulatory T cells EVE-Treg combined with daily low-dose Interleukin-2 IL-2 for treating steroid-refractory chronic graft-versus-host disease cGVHD. cGVHD is a serious complication that can occur months after hematopoietic stem cell transplant HCT, which is used to treat blood cancers such as leukemia and lymphoma. The study aims to assess the safety and effects of this combined approach in patients whose cGVHD has not responded to standard treatments. Participants receive one dose of EVE-Treg cells at one of three dose levels A, B, or C while continuing daily low-dose IL-2 injections. This phase I trial uses a sequential study design to evaluate different doses of the investigational cell therapy. The treatment period is followed by monitoring to assess safety and response over 5 weeks. During the study, participants undergo evaluations including monitoring for side effects and disease status. Researchers will track how well participants tolerate the cell therapy combined with IL-2 and measure safety outcomes. The total participation time includes the treatment and follow-up period, with close observation to understand the impact of the therapy on cGVHD symptoms and patient health.

CONDITIONS

Brief Title

Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

Research Team

B

Brandi Bratrude

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here